Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:52 UTC |
---|
Update Date | 2022-03-07 02:52:03 UTC |
---|
HMDB ID | HMDB0015605 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Tamibarotene |
---|
Description | Tamibarotene is only found in individuals that have used or taken this drug. It is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.Tamibarotene is a specific agonist for retinoic acid receptor alpha/beta with possible binding to retinoid X receptors (RXR). |
---|
Structure | CC1(C)CCC(C)(C)C2=C1C=CC(NC(=O)C1=CC=C(C=C1)C(O)=O)=C2 InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26) |
---|
Synonyms | Value | Source |
---|
Am 80 | ChEBI | Am-80 | ChEBI | Amnoid | ChEBI | Retinobenzoic acid | ChEBI | Tamibaro | ChEBI | Retinobenzoate | Generator | 4-((5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl)benzoic acid | HMDB |
|
---|
Chemical Formula | C22H25NO3 |
---|
Average Molecular Weight | 351.4388 |
---|
Monoisotopic Molecular Weight | 351.183443671 |
---|
IUPAC Name | 4-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbamoyl]benzoic acid |
---|
Traditional Name | tamibarotene |
---|
CAS Registry Number | 94497-51-5 |
---|
SMILES | CC1(C)CCC(C)(C)C2=C1C=CC(NC(=O)C1=CC=C(C=C1)C(O)=O)=C2 |
---|
InChI Identifier | InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26) |
---|
InChI Key | MUTNCGKQJGXKEM-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Tetralins |
---|
Sub Class | Not Available |
---|
Direct Parent | Tetralins |
---|
Alternative Parents | |
---|
Substituents | - Tetralin
- Benzamide
- Benzoic acid or derivatives
- Benzoic acid
- Benzoyl
- Monocyclic benzene moiety
- Secondary carboxylic acid amide
- Carboxamide group
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Carboxylic acid derivative
- Hydrocarbon derivative
- Organic nitrogen compound
- Organooxygen compound
- Organonitrogen compound
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Aromatic homopolycyclic compound
|
---|
Molecular Framework | Aromatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.00058 g/L | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Tamibarotene,1TMS,isomer #1 | CC1(C)CCC(C)(C)C2=CC(NC(=O)C3=CC=C(C(=O)O[Si](C)(C)C)C=C3)=CC=C21 | 3310.1 | Semi standard non polar | 33892256 | Tamibarotene,1TMS,isomer #2 | CC1(C)CCC(C)(C)C2=CC(N(C(=O)C3=CC=C(C(=O)O)C=C3)[Si](C)(C)C)=CC=C21 | 3170.3 | Semi standard non polar | 33892256 | Tamibarotene,2TMS,isomer #1 | CC1(C)CCC(C)(C)C2=CC(N(C(=O)C3=CC=C(C(=O)O[Si](C)(C)C)C=C3)[Si](C)(C)C)=CC=C21 | 2978.9 | Semi standard non polar | 33892256 | Tamibarotene,2TMS,isomer #1 | CC1(C)CCC(C)(C)C2=CC(N(C(=O)C3=CC=C(C(=O)O[Si](C)(C)C)C=C3)[Si](C)(C)C)=CC=C21 | 2980.7 | Standard non polar | 33892256 | Tamibarotene,2TMS,isomer #1 | CC1(C)CCC(C)(C)C2=CC(N(C(=O)C3=CC=C(C(=O)O[Si](C)(C)C)C=C3)[Si](C)(C)C)=CC=C21 | 2941.7 | Standard polar | 33892256 | Tamibarotene,1TBDMS,isomer #1 | CC1(C)CCC(C)(C)C2=CC(NC(=O)C3=CC=C(C(=O)O[Si](C)(C)C(C)(C)C)C=C3)=CC=C21 | 3561.9 | Semi standard non polar | 33892256 | Tamibarotene,1TBDMS,isomer #2 | CC1(C)CCC(C)(C)C2=CC(N(C(=O)C3=CC=C(C(=O)O)C=C3)[Si](C)(C)C(C)(C)C)=CC=C21 | 3437.6 | Semi standard non polar | 33892256 | Tamibarotene,2TBDMS,isomer #1 | CC1(C)CCC(C)(C)C2=CC(N(C(=O)C3=CC=C(C(=O)O[Si](C)(C)C(C)(C)C)C=C3)[Si](C)(C)C(C)(C)C)=CC=C21 | 3498.6 | Semi standard non polar | 33892256 | Tamibarotene,2TBDMS,isomer #1 | CC1(C)CCC(C)(C)C2=CC(N(C(=O)C3=CC=C(C(=O)O[Si](C)(C)C(C)(C)C)C=C3)[Si](C)(C)C(C)(C)C)=CC=C21 | 3400.9 | Standard non polar | 33892256 | Tamibarotene,2TBDMS,isomer #1 | CC1(C)CCC(C)(C)C2=CC(N(C(=O)C3=CC=C(C(=O)O[Si](C)(C)C(C)(C)C)C=C3)[Si](C)(C)C(C)(C)C)=CC=C21 | 3184.9 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Tamibarotene GC-MS (Non-derivatized) - 70eV, Positive | splash10-0002-0926000000-4e20d564460f24f3bee6 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Tamibarotene GC-MS (1 TMS) - 70eV, Positive | splash10-00di-3195400000-2f9ea0b192db22b23e34 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Tamibarotene GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tamibarotene 10V, Positive-QTOF | splash10-0ue9-0009000000-dbfed4dced06a8666457 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tamibarotene 20V, Positive-QTOF | splash10-053r-1239000000-eb277707477e13926eb0 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tamibarotene 40V, Positive-QTOF | splash10-0kii-4930000000-87f3d164d219001d818b | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tamibarotene 10V, Negative-QTOF | splash10-0udi-0009000000-8077c73aa7a0b3a0493f | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tamibarotene 20V, Negative-QTOF | splash10-0pb9-1119000000-0596ca0316feae6135e6 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tamibarotene 40V, Negative-QTOF | splash10-00bc-9621000000-472a8ced02b76b7e0310 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tamibarotene 10V, Positive-QTOF | splash10-0udi-0019000000-d9e09ce3c5ade8ebd024 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tamibarotene 20V, Positive-QTOF | splash10-0gwb-0369000000-6c232cbaf08e18c9b277 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tamibarotene 40V, Positive-QTOF | splash10-0a4j-3921000000-fbd8a12bd61c31548a10 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tamibarotene 10V, Negative-QTOF | splash10-0udi-0009000000-3ef35313b76eb3af9c7e | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tamibarotene 20V, Negative-QTOF | splash10-0udi-0009000000-986ece158863bf5eb6b0 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tamibarotene 40V, Negative-QTOF | splash10-001i-2090000000-faa1fb3b6d57e52a9c4c | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|
General References | - Miwako I, Kagechika H: Tamibarotene. Drugs Today (Barc). 2007 Aug;43(8):563-8. [PubMed:17925887 ]
- Sanda T, Kuwano T, Nakao S, Iida S, Ishida T, Komatsu H, Shudo K, Kuwano M, Ono M, Ueda R: Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis. Leukemia. 2005 Jun;19(6):901-9. [PubMed:15843826 ]
- Authors unspecified: Tamibarotene: AM 80, retinobenzoic acid, Tamibaro. Drugs R D. 2004;5(6):359-62. [PubMed:15563242 ]
- Mizojiri K, Okabe H, Sugeno K, Misaki A, Ito M, Kominami G, Esumi Y, Takaichi M, Harada T, Seki H, Inaba A: Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. Arzneimittelforschung. 1997 Mar;47(3):259-69. [PubMed:9105544 ]
- Takeuchi M: [Clinical experience with a new synthetic retinoid, tamibarotene (Am-80) for relapsed or refractory acute promyelocytic leukemia]. Gan To Kagaku Ryoho. 2006 Mar;33(3):397-401. [PubMed:16531727 ]
|
---|